三苯乙酸维兰特罗(Vilanterol Trifenatate) - 药物靶点：β2-adrenergic receptor_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Vilanterol、Vilanterol trifenatate (JAN/USAN)、GSK-642444

+ [8]

靶点

β2-adrenergic receptor

作用方式

激动剂

作用机制

β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂)

治疗领域

免疫系统疾病感染心血管疾病+ [2]

在研适应症-

非在研适应症

气道病变过敏性哮喘哮喘+ [5]

原研机构

GSK Plc

在研机构-

非在研机构

GSK PlcGlaxoSmithKline Research & Development Ltd.

权益机构

GSK Plc

Theravance Biopharma, Inc.

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构/序列

分子式C44H49Cl2NO7

InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N

CAS号503070-58-4

关联

115

项与三苯乙酸维兰特罗相关的临床试验

CTRI/2025/12/098826

/ Not yet recruiting临床4期

A prospective, open label, single-arm, multicentre, phase IV clinical trial to assess efficacy and safety of Vilanterol,Glycopyrronium and Fluticasone furoate powder for Inhalation in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) - NIL

开始日期2025-12-20

申办/合作机构

Zydus Healthcare Ltd.

CTRI/2025/04/085135

/ Not yet recruiting临床4期

A prospective, open label, single-arm, multicentre, active post-marketing surveillance study to assess safety and effectiveness of Vilanterol 25 mcg and Fluticasone Furoate 200 mcg powder for inhalation in patients with asthma. - NIL

开始日期2025-05-01

申办/合作机构

Zydus Healthcare Ltd.

CTRI/2025/02/080495

/ Recruiting临床3期

A prospective, randomized, double-blind, parallel, active-controlled, multicentre, phase III clinical trial to assess the efficacy and safety of Vilanterol, Umeclidinium and Fluticasone furoate inhalation as compared to Vilanterol and Fluticasone furoate inhalation in patients with uncontrolled asthma. - NIL

开始日期2025-02-24

申办/合作机构

Zydus Healthcare Ltd.

100 项与三苯乙酸维兰特罗相关的临床结果

登录后查看更多信息

100 项与三苯乙酸维兰特罗相关的转化医学

登录后查看更多信息

100 项与三苯乙酸维兰特罗相关的专利（医药）

登录后查看更多信息

599

项与三苯乙酸维兰特罗相关的文献（医药）

2026-05-01·Respiratory Investigation

Adherence to single-inhaler triple therapies in middle-aged patients with chronic obstructive pulmonary disease: A group-based trajectory analysis

Article

作者: Miyamoto, Atsushi ; Yoshida, Satomi ; Fukasawa, Toshiki ; Kawakami, Koji ; Watanabe, Tetsuya ; Asai, Kazuhisa ; Hirai, Kaho ; Liu, Hao ; Akaike, Takenori

BACKGROUND:

Middle-aged patients with chronic obstructive pulmonary disease (COPD) initiating single-inhaler triple therapy (SITT) exhibit heterogeneous adherence trajectories. To clarify differences in the timing of adherence decline and identify patients at risk of poor adherence, we conducted a descriptive study to classify these patterns.

METHODS:

We identified COPD patients aged 40 to 64 years who initiated fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or budesonide/glycopyrronium/formoterol (BUD/GLY/FOR) using a Japanese claims database. Group-based trajectory modeling was used to analyze the monthly proportion of days covered over time, with groups classified by similar 360-day adherence trajectories.

RESULTS:

1075 patients were included in the analysis for FF/UMEC/VI and 638 patients for BUD/GLY/FOR. Five adherence groups were identified among patients initiating FF/UMEC/VI: (1) a consistently high group (25.2%), (2) a gradually declining group (12.2%), (3) a rapidly declining adherence group (12.3%), (4) an early-decline/partial-recovery group (6.4%), and (5) an immediately declining group (43.9%). Similarly, five adherence groups were also seen among BUD/GLY/FOR initiators: (1) a consistently high group (17.1%), (2) a gradually declining group (5.0%), (3) a rapidly declining group (12.7%), (4) a moderately stable group (12.9%), and (5) an immediately declining group (52.4%). In both cohorts, higher adherence groups tended to be older and have more comorbidities, while suboptimal adherence groups were more often female, had fewer prior treatments, and began SITT in clinics.

CONCLUSIONS:

We identified distinct adherence patterns among middle-aged COPD patients initiating treatment with FF/UMEC/VI or BUD/GLY/FOR. Understanding the characteristics of these patterns may enable more targeted interventions to improve adherence and patient outcomes.

2026-05-01·ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Relative particle size and distribution of inhaled triple therapies

Article

作者: Agazzi, Ruben ; Zambelli, Enrico ; Piraino, Alessio ; Lipworth, Brian

BACKGROUND:

Many patients with asthma or chronic obstructive pulmonary disease have small airways dysfunction, the presence of which has clinical implications including poor disease control and worse health status. It is, therefore, important to evaluate the ability of an inhaled product used for the treatment of asthma or chronic obstructive pulmonary disease to penetrate the small airways.

OBJECTIVE:

To compare the aerodynamic particle size distribution of 3 triple combination inhalers: beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G), budesonide/formoterol fumarate/glycopyrronium (BUD/FF/G), and fluticasone furoate/vilanterol/umeclidinium (FLU/VI/UMEC).

METHODS:

Parameters evaluated via a Next Generation Impactor analysis included particle size as mass median aerodynamic diameter and extrafine particle fraction (eFPF; diameter < 2 µm) calculated as a percentage of the delivered dose. The mass of each component was evaluated using high-performance liquid chromatography assays (FF as the dihydrate salt, G as the bromide salt, VI as the trifenatate salt, and UMEC as the bromide salt).

RESULTS:

Mass median aerodynamic diameter values for all 3 components of BDP/FF/G were consistent (1.1 µm) and were lower than BUD/FF/G (3.02-3.36 µm) and FLU/VI/UMEC (1.96-4.13 µm). Mean eFPFs of the 3 components of BDP/FF/G were also consistent (39.0%-39.9%) and were higher than those of the other 2 therapies (BUD/FF/G, 10.5%-16.2%; FLU/VI/UMEC, 6.8%-27.7%), especially for the BDP component, which was 3.8-fold higher than BUD and 5.8-fold higher than FLU.

CONCLUSION:

BDP/FF/G delivers consistently smaller particles than either BUD/FF/G or FLU/VI/UMEC, translating into a commensurate higher eFPF, in turn suggesting greater potential to target the small airways.

2026-04-03·Expert Review of Respiratory Medicine

Is dual bronchodilation a cost-effective alternative to ICS/LABA in COPD? A Colombian healthcare system evaluation

Article

作者: Patiño, Diana Guerrero ; Buendía, Jefferson Antonio

BACKGROUND:

Chronic obstructive pulmonary disease (COPD) is a major public health challenge in Colombia, particularly among older adults. Although ICS/LABA combinations like fluticasone/salmeterol (FSC) are widely used, dual bronchodilation with umeclidinium/vilanterol (UMEC/VI) may offer clinical and economic advantages.The objective of this paper is to evaluate the long-term cost-effectiveness of UMEC/VI versus FSC in patients with moderate to severe COPD from the perspective of the Colombian healthcare system.

METHODS:

A Markov model with four health states (moderate, severe, very severe COPD, and death) simulated the disease course over a lifetime horizon. Clinical efficacy and utilities were derived from randomized trials and meta-analyses; costs were sourced from national databases. Deterministic and probabilistic sensitivity analyses assessed uncertainty. The economic advantage of UMEC/VI was primarily driven by its ability to reduce moderate and severe exacerbations, which represent nearly 88% of total COPD-related healthcare costs in Colombia.

RESULTS:

UMEC/VI yielded 8.74 additional QALYs compared to FSC, with an incremental cost of $7,039 USD, resulting in an ICER of $805 per QALY-well below Colombia's WTP threshold of $5,180. Sensitivity analyses confirmed model robustness; UMEC/VI remained cost-effective in 64% of simulations.

CONCLUSION:

UMEC/VI is a highly cost-effective alternative to FSC for moderate to severe COPD in Colombia, offering improved clinical outcomes and economic value for resource-constrained health systems.

75

项与三苯乙酸维兰特罗相关的新闻（医药）

2026-05-11

·BioSpace

Transpire Bio’s ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA

SUNRISE, Fla. , May 11, 2026 /PRNewswire/ -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of the high-strength Trelegy ® Ellipta ®1 (200 mcg/62.5 mcg/25 mcg) product, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Based on the FDA's public records, 2 Transpire Bio believes that it was the first company to ANDA for the high-strength product with a Paragraph IV certification under the provisions of the Hatch-Waxman Act. Should Transpire Bio's ANDA be approved by the FDA, Transpire Bio believes it will be eligible for 180 days of market exclusivity. In the U.S., Trelegy ® Ellipta ® is indicated for the maintenance treatment of asthma in patients 18 years and older and the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). According to IQVIA, Trelegy ® Ellipta ® reported U.S. annual sales of $8 Billion in 2025. 3 "The FDA's acceptance of our ANDA filing for the substitutable generic version of high-strength Trelegy ® Ellipta ® is another major milestone in advancing our development program and our complex generic franchise as a whole," said Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio. "Our highly experienced team in South Florida continues to meet and exceed each challenge put in front of them. With our first two ANDAs for generic Breo ® and Trelegy ® now confirmed as first-to-file, and this ANDA as our potentially third first-to-file, we move one step closer to providing patients suffering from asthma or COPD with an affordable option and improved access to this critical medication." "This milestone demonstrates Transpire Bio's strong capabilities in developing complex drug device combination products. We are extremely proud of the deep scientific and technical competence of our Transpire Bio team to constantly execute against our strategic plan," said Dr. Abhishek Gupta, Chief Scientific Officer of Transpire Bio. In addition to its focused complex generic franchise, Transpire Bio is building a pipeline of innovative inhalation medicines for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), with three assets in development. Transpire Bio is also developing therapies for Pulmonary Arterial Hypertension (PAH), Diabetes, Obesity, Parkinson's Disease Psychosis, and Glioblastoma. These products are being developed and manufactured in Transpire Bio's state-of-the-art manufacturing facilities located in South Florida, U.S. Trelegy ® Ellipta ® is a registered trademark of the GSK group of companies. FDA’s “Paragraph IV” patent certification list IQVIA NPA (US SMART Edition). Data on file. About Transpire Bio Inc. Transpire Bio Inc. is an integrated US-based, clinical-stage biopharmaceutical company headquartered in Sunrise, Florida. Transpire Bio is innovating by applying its deep inhalation drug formulation and delivery expertise to respiratory and systemic diseases where currently available options are significantly lacking. Transpire Bio has developed multiple proprietary inhalation technology platforms, including dry-powder inhalers and soft-mist inhalers, and is progressing a pipeline of innovative inhalation medicines for Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF), Pulmonary Arterial Hypertension (PAH), Diabetes, Obesity, Parkinson's Disease Psychosis, and Glioblastoma. For more information, please visit . View original content to download multimedia: SOURCE Transpire Bio

2026-02-25

·drugs

Umeclidinium-Vilanterol Tied to Better Outcomes Than Other LAMA-LABA Inhalers in Symptomatic COPD

WEDNESDAY, Feb. 25, 2026 -- Umeclidinium-vilanterol is associated with improved clinical outcomes compared with glycopyrrolate-formoterol and tiotropium-olodaterol in symptomatic patients with chronic obstructive pulmonary disease (COPD), according to a study published online Feb. 23 in JAMA Internal Medicine . Gerard T. Portela, Ph.D., from Brigham and Women’s Hospital in Boston, and colleagues evaluated the comparative effectiveness and safety of once-daily umeclidinium-vilanterol dry powder inhalers, twice-daily glycopyrrolate-formoterol metered-dosed inhalers, and once-daily tiotropium-olodaterol soft mist inhalers. The analysis included claims data from 55,817 matched pairs (aged 40 years and older) newly treated with long-acting muscarinic antagonist–long-acting β 2 -agonist (LAMA-LABA) inhalers and continuously enrolled in a large commercial health insurance or Medicare Advantage plan during a 183-day baseline period. The researchers found that umeclidinium-vilanterol was associated with a lower risk for a first moderate or severe COPD exacerbation versus glycopyrrolate-formoterol (hazard ratio [HR], 0.86; 95 percent confidence interval, 0.81 to 0.91; number needed to treat [NNT], 17). Umeclidinium-vilanterol also was associated with a lower risk compared with tiotropium-olodaterol (HR, 0.97; 95 percent confidence interval, 0.94 to 0.99; NNT, 100). Compared with glycopyrrolate-formoterol, tiotropium-olodaterol tended to be associated with a lower risk for a first moderate or severe COPD exacerbation (HR, 0.94; 95 percent confidence interval, 0.89 to 1.00). Across all three groups, the risks for first major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization were similar. "Patients, prescribers, and health systems may consider once-daily umeclidinium-vilanterol dry powder inhalers over alternatives among new users of LAMA-LABA therapy," the authors write. Several authors disclosed ties to the pharmaceutical industry. Abstract/Full Text (subscription or payment may be required)

临床结果

2026-02-24

·drugs

Dry Powder Inhalers: A Double Win for COPD and Environment

TUESDAY, Feb. 24, 2026 — Dry powder inhalers might provide a double benefit for people battling chronic obstructive pulmonary disease (COPD), a new study says. These inhalers not only lead to slightly better lung health among COPD patients, but also are less harmful to the environment, researchers reported Feb. 23 in JAMA Internal Medicine . The most commonly prescribed dry powder inhaler for COPD outperformed the most common metered-dose inhaler, researchers found. Metered-dose inhalers rely on propellants to deliver drugs to the lungs — potent greenhouse gases that contribute to climate change, researchers noted. “The inhalers we studied are the first line treatment for many patients with COPD, so it’s reassuring to see evidence that lower-emission inhalers may also be associated with slightly better clinical outcomes,” said senior researcher Dr. William Feldman , a pulmonologist and health services researcher at UCLA Health. “These findings highlight the opportunity to reduce health care-related emissions while potentially improving patient care,” he said in a news release. For the new study, researchers compared nearly 9,500 COPD patients using a dry powder inhaler against the same number using a metered-dose inhaler. Patients using a dry powder inhaler must breathe in their medicine, rather than having it pushed into the lungs by an aerosol spray. Results showed that a dry powder inhaler loaded with umeclidinium and vilanterol produced a 14% lower risk of moderate or severe COPD flare-ups, compared to a metered-dose inhaler loaded with glycopyrrolate and formoterol . A soft mist inhaler loaded with tiotropium and olodaterol also did slightly better, lowering flare-up risk by 6% compared to a metered-dose inhaler among nearly 9,600 matched pairs. Soft mist inhalers also don’t rely on propellants. “This combination makes a strong case for using the dry powder inhaler when possible,” Feldman said. “Although some patients may require metered-dose inhalers, dry powder inhalers and soft mist inhalers are a safe and effective option for most patients with COPD.” Sources UCLA, news release, Feb. 23, 2026

临床结果

100 项与三苯乙酸维兰特罗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09697	三苯乙酸维兰特罗	-	DB09082

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性支气管炎	临床3期	捷克	GlaxoSmithKline Research & Development Ltd.	2012-05-31
心血管疾病	临床3期	捷克	GlaxoSmithKline Research & Development Ltd.	2012-05-31
僵硬	临床3期	美国	GSK Plc	2011-03-04
僵硬	临床3期	德国	GSK Plc	2011-03-04
僵硬	临床3期	挪威	GSK Plc	2011-03-04
僵硬	临床3期	菲律宾	GSK Plc	2011-03-04
僵硬	临床3期	韩国	GSK Plc	2011-03-04
僵硬	临床3期	泰国	GSK Plc	2011-03-04
持续性哮喘	临床3期	荷兰	GlaxoSmithKline Research & Development Ltd.	2010-06-22
哮喘	临床3期	德国	GlaxoSmithKline Research & Development Ltd.	2010-03-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ATS2025	临床3期	哮喘 \| 炎症维持 blood eosinophils \| fractional exhaled nitric oxide	-	Fluticasone Furoate/Umeclidinium/Vilanterol	鑰範餘淵醖餘膚簾鹽選(蓋鬱顧繭構顧鹹衊鏇範) = 構餘齋遞鹹壓觸衊衊夢願鑰鹽蓋壓製觸衊鹽製 (齋憲壓齋廠製遞範範簾 )	-	2025-05-16
				Fluticasone Furoate/Vilanterol	鑰範餘淵醖餘膚簾鹽選(蓋鬱顧繭構顧鹹衊鏇範) = 簾製遞壓選網簾顧齋壓願鑰鹽蓋壓製觸衊鹽製 (齋憲壓齋廠製遞範範簾 )
ATS2025	临床3期	慢性阻塞性肺疾病	4,151	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)	襯憲餘積壓構夢膚壓觸(夢蓋壓醖窪選憲選憲蓋) = 顧醖築窪簾觸艱網淵製艱遞窪簾鹽艱醖壓衊築 (廠積廠廠鏇餘襯襯糧膚 ) 更多	积极	2025-05-16
				Fluticasone Furoate/Vilanterol (FF/VI)	襯憲餘積壓構夢膚壓觸(夢蓋壓醖窪選憲選憲蓋) = 積積憲蓋觸獵願簾鬱艱艱遞窪簾鹽艱醖壓衊築 (廠積廠廠鏇餘襯襯糧膚 ) 更多
ELLITHE (ERS2024)	N/A	慢性阻塞性肺疾病	617	Fluticasone furoate+Umeclidinium+Vilanterol	鑰糧醖選獵遞衊遞範憲(簾廠夢淵觸齋夢鹹鏇製) = 艱鹽繭醖廠遞繭襯願蓋獵範簾遞膚選窪夢鏇範 (糧廠顧顧築構鏇積艱顧 ) 更多	积极	2024-09-07
ERS2023	N/A	慢性阻塞性肺疾病	5,537	Multiple inhaler triple therapy (MITT)	鏇築網構範壓壓築獵網(簾鬱壓製艱淵選艱製壓) = 網鏇願淵糧蓋窪範簾願壓膚鹹憲齋繭襯範鹹壓 (遞鬱遞鹹夢艱糧窪鹽鏇 )	积极	2023-09-09
NCT02164513 (IMPACT, Pubmed \| Am J Respir Crit Care Med)	临床3期	慢性阻塞性肺疾病	-	Fluticasone Furoate/Umeclidinium/Vilanterol 100/62.5/25µg	醖鹹壓鏇壓鏇願觸壓膚(壓廠築鏇蓋築獵繭廠衊): hazard ratio = 0.89 (95% CI, 0.67 ~ 1.16), P-Value = 0.387	积极	2020-06-15
				Fluticasone Furoate/Vilanterol 100/25µg
NCT02164513 (IMPACT, Pubmed \| Respir Res)	临床3期	慢性阻塞性肺疾病	7,012	Fluticasone furoate/umeclidinium/vilanterol	願獵獵鏇衊醖獵夢鬱窪(網齋構鹽鹹鑰鏇蓋鹹獵) = 遞鹹醖構糧獵積廠鹹獵獵窪襯繭衊製願廠糧蓋 (餘壓憲鑰鑰範夢繭鏇襯 )	积极	2020-06-05
				Fluticasone furoate/vilanterol	願獵獵鏇衊醖獵夢鬱窪(網齋構鹽鹹鑰鏇蓋鹹獵) = 願蓋夢鑰製選繭觸廠憲獵窪襯繭衊製願廠糧蓋 (餘壓憲鑰鑰範夢繭鏇襯 )
NCT01957150 (CTgov)	临床4期	慢性阻塞性肺疾病	283	VI (Participants Administered VI)	鹹遞窪鹹網積鑰襯憲鏇(鹹糧獵餘壓艱顧鹹齋艱) = 淵簾淵壓觸選顧餘鑰鏇餘醖鏇鬱憲積窪鏇糧鹹 (餘鹽齋齋憲膚憲繭顧構, 製範鬱構艱觸繭構糧遞 ~ 鑰淵構鏇齋襯構窪廠鏇) 更多	-	2019-04-10
				VI (Participants Administered FF/VI)	鹹遞窪鹹網積鑰襯憲鏇(鹹糧獵餘壓艱顧鹹齋艱) = 選選齋觸築鬱觸餘鏇蓋餘醖鏇鬱憲積窪鏇糧鹹 (餘鹽齋齋憲膚憲繭顧構, 遞願窪獵鏇顧遞餘艱鬱 ~ 鹹積膚淵鹹積鑰膚憲顧) 更多
NCT01313676 (SUMMIT, Pubmed \| ERJ Open Res)	临床3期	慢性阻塞性肺疾病	-	Fluticasone furoate (FF)	膚襯觸蓋蓋窪製鬱顧製(淵艱齋膚憲衊餘積鑰獵): hazard ratio = 0.65 (95% CI, 0.48 ~ 0.89)	-	2019-02-01
				Placebo
NCT02446418 (CTgov)	临床3期	持续性哮喘	423	ICS (Usual ICS/LABA)	淵憲選鑰醖製顧製願鏇(製衊遞鹹膚鏇製鬱繭選) = 衊鑰範構窪顧膚淵醖鏇憲餘壓鏇憲艱膚淵膚製 (鹽獵窪襯顧夢醖築襯願, 0.26) 更多	-	2019-01-14
				VI+Vilanterol (FF/VI)	淵憲選鑰醖製顧製願鏇(製衊遞鹹膚鏇製鬱繭選) = 鹹壓廠夢夢鬱壓壓憲構憲餘壓鏇憲艱膚淵膚製 (鹽獵窪襯顧夢醖築襯願, 0.26) 更多
NCT02712047 (CTgov)	临床2期	哮喘 \| 气道病变	28	Placebo	醖簾夢觸築觸襯夢鑰鏇(積遞製壓醖積衊廠齋醖) = 範觸選憲構繭廠夢選願鹽衊膚鹹選鹽積膚壓鹹 (憲廠壓觸窪襯夢顧繭壓, 31.5499) 更多	-	2018-08-28